Hypertensive optic neuropathy.

J L Smith; Y Goldhammer

PubMed · 1080308

Hypertensive optic neuropathy.

Abstract

In 1970 a 62-year-old physician with hypertensive vascular disease suffered a small infarction in the left optic disc, which left him with a subtle paracentral temporal visual field defect in that eye. In 1973 he had another separate and distinct episode in the same eye, which produced a dense lower nasal field defect. Careful Hruby lens examination of the disc under high magnification revealed focal arteriolar disease in the optic nerve head corresponding to the field defects, and fluorescein angiography confirmed these findings. The importance of differentiating ischemic optic neuropathy, hypertensive optic neuropathy, and temporal arteritis with optic nerve involvement is emphasized, and the therapy of each is discussed.

Explore related subjects

Color Vision Defects Diagnosis, Differential Fluorescein Angiography Fundus Oculi Giant Cell Arteritis Humans Hypertension Infarction Ischemia Male Middle Aged Optic Disk Optic Neuritis Recurrence Scotoma Vascular Diseases Visual Fields Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J L Smith, Y Goldhammer. Hypertensive optic neuropathy.. https://pubmed.ncbi.nlm.nih.gov/1080308/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

An effect of luminance contrast on high-spatial-frequency tritanopia.

Luminance contrast was found to affect high-spatial-frequency tritanopia despite the S-cone coordinates of the stimuli being kept constant. This proves that a traditional account of artificial tritanopias based on the spatial resolution differences between the S-cone channel and the M- and L-cone channels is not applicable here. We suggest that the lack of spatial resolution in one of the post-receptor (rather than receptor) spatio-chromatic channels could be a cause of high-spatial-frequency tritanopia.

Color Vision Defects↗

PubMed2006

Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction.

Sildenafil citrate improves erectile function in men with erectile dysfunction (ED) by selectively inhibiting cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), which is present in all vascular tissue. Sildenafil also has a weaker inhibitory action on PDE6, located in the rod and cone photoreceptors. Modest, transient visual symptoms, typically blue tinge to vision, increased brightness of lights, and blurry vision, have been reported with sildenafil use and occur more frequently at higher doses. Visual function studies in healthy subjects and in patients with eye disease suggest that sildenafil does not affect visual acuity, visual fields, and contrast sensitivity. Transient, mild impairment of color discrimination can occur around the time of peak plasma levels. Spontaneous postmarketing reports of visual adverse events, including nonarteritic anterior ischemic optic neuropathy (NAION), have been reported during the 7 years that sildenafil has been prescribed to more than 27 million men worldwide. However, because men with ED frequently have vascular risk factors that may also put them at increased risk for NAION, a causal relationship is difficult to establish. No consistent pattern has emerged to suggest any long-term effect of sildenafil on the retina or other structures of the eye or on the ocular circulation.

Color Vision Defects↗

PubMed2005

Simulation of color deficiency in virtual reality.

Color deficiency protanopia is simulated in a virtual home environment. A color database is created to set the corresponding relation between each color for normal vision and for protanopia. Based on this database, a second texture system is set up for the home model. The proper texture system is used according to the user's choice on the interactive menu.

Color Vision Defects↗